Originally dba Vasculox, Inc., in 2016 the firm was renamed Tioma Therapeutics and appears to have been renamed again as Arch Oncology(?). With research facilities continuing in St Louis, MO and a facility in Brisbane CA, this renamed entiity is a biotechnology company focused on novel therapies for disorders driven by CD47 signaling pathways. Continuing the work begun as Vasculox, the firm is developing a portfolio of anti-CD47 therapeutic antibodies for the treatment of cancer and pulmonary hypertension, the prevention of certain complications of solid organ transplantation, and other important medical applications. Products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. Vasculoxs platform technology is based on a previously unknown mode of vascular regulation to prevent tissue ischemia as a result of trauma, surgery or vascular disease. The firm's products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor.
